A director at US Foods Holding Corp bought 4,000 shares at 71.060USD and the significance rating of the trade was 84/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
A director at CVS Health Corp bought 30,000 shares at 66.700USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares NEW YORK and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- e Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on February 14, 2025, the closing of its public offering of 26,190,477 common shares occurred. Additionally, on February 17, 2025, the underwriter exercised its option in full to purchase an additional 3,928,571 common shares at the public...
ROSEMONT, Ill.--(BUSINESS WIRE)-- US Foods Holding Corp. (NYSE: USFD), one of the largest foodservice distributors in the United States, is participating at the 2025 Consumer Analyst Group of New York (CAGNY) Conference today at 11 a.m. EST. Dave Flitman, Chief Executive Officer, and Dirk Locascio, Chief Financial Officer, will present at the conference. “We overachieved our 2022 to 2024 long range plan through the focused execution of our strategy, where we delivered an Adjusted EBITDA increase of 11.7% to $1.74 billion in 20241,” said Dave Flitman, Chief Executive Officer. “Building on this...
ROSEMONT, Ill.--(BUSINESS WIRE)-- US Foods Holding Corp. (NYSE: USFD), one of the largest foodservice distributors in the United States, today announced results for the fourth quarter and full fiscal year 2024. Fourth Quarter Fiscal 2024 Highlights Total case volume increased 3.5%; independent restaurant case volume increased 3.2% Net sales increased 6.2% to $9.5 billion Gross profit increased 4.8% to $1.7 billion Net income was $66 million Adjusted EBITDA increased 13.7% to $441 million Diluted EPS decreased 52.5% to $0.28; Adjusted Diluted EPS increased 31.3% to $0.84 ...
atai Life Sciences Announces Pricing of Public Offering of Common Shares NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 26,190,477 common shares, at a price of $2.10 per share. atai has granted the underwriter a 30-day option to purchase up to an additional 3,928,571 common shares. All common shares to be sold in the offering will be sold by atai. The gross proceed...
atai Life Sciences Announces Proposed Public Offering of Common Shares NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of $55,000,000 of its common shares. atai expects to grant the underwriter a 30-day option to purchase up to an additional $8,250,000 of common shares. All common shares to be sold in the offering will be sold by atai. atai intends to use t...
Two Directors at Helmerich & Payne Inc bought 57,356 shares at between 27.080USD and 27.550USD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ...
ROSEMONT, Ill.--(BUSINESS WIRE)-- US Foods Holding Corp. (NYSE: USFD) today announced that Dave Flitman, Chief Executive Officer, and Dirk Locascio, Chief Financial Officer, will present at the CAGNY 2025 Conference on Thursday, Feb. 20, 2025, at 11 a.m. EST. The Company will webcast live from the event, which can be accessed at An archived replay of the webcast will be available shortly after the live event is completed. About US Foods With a promise to help its customers Make It, US Foods is one of America’s great food companies and a leading foodservice distributor, partnering with a...
TULSA, Okla.--(BUSINESS WIRE)-- Helmerich & Payne, Inc. (NYSE: HP) reported net income of $55 million, or $0.54 per diluted share, from operating revenues of $677 million for the quarter ended December 31, 2024, compared to net income of $75 million, or $0.76 per diluted share, from operating revenues of $694 million for the quarter ended September 30, 2024. The net income per diluted share for the first quarter of fiscal 2025 and fourth quarter of fiscal year 2024 include net $(0.17) and $0.00 of after-tax gains and losses, respectively, comprised of select items(1). Net cash provided by op...
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder - A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three months - BPL-003 was well-tolerated with no serious or severe adverse events reported NEW YORK and BERLIN, Jan. 28, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aimin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.